Opens in a new tab

GXD-Bio v Myriad International (CFI, 26 November 2024)

Date26 November 2024
CourtCFI
DivisionMunich (DE) Local Division
Type of actionGeneric application
Registry referenceApp_59539/2024 · ORD_59602/2024
PartiesMyriad Service GmbH, Myriad Genetics, Inc., Myriad International GmbH, Myriad Genetics B.V., Eurobio Scientific, Myriad Genetics S.r.l., My…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 26 November 2024 (UPC_CFI_437/2024, ACT_43382/2024, ORD_59602/2024), the judge-rapporteur of the Munich Local Division (U. Voß), in GXD-Bio Corporation’s infringement action on EP 3 346 403 against Myriad International GmbH and eight other defendants, ordered the claimant to provide security of EUR 112,000 for the defendants’ costs by 15 January 2025, but declined to make a decision by default in advance.

Question

Should security for costs be ordered against a recently incorporated Korean patent monetisation company, and can a default decision be made in advance in case security is not provided?

Decision

The court has discretion, taking into account in particular the claimant’s financial position and the risk that a costs order may not be recoverable or enforceable. The requesting party must give reasons and the other side must contest them with substance. As the defendants’ financial information was undisputed, the risk of non-recovery was real, and the claimant did not argue that security would impair its right to an effective remedy. The choice between deposit and bank guarantee was left open, and the period of about seven weeks took account of the holidays. The request for a default decision was premature, as no time limit had yet been set. The claimant was merely warned of the risk under Rule 355. Leave to appeal was granted to the defendants.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 69(4) and 73(2)(b)(ii)
Rules of Procedure
Rules 158.1, 220.2 and 355
Case law cited
Court of Appeal, 17 September 2024 (UPC_CoA_218/2024), Edwards Lifesciences v Meril, Munich Local Division, 29 September 2023, President and Fellows of Harvard College v NanoString, Munich Central Division, 30 October 2023, AIM Sport Vision v Supponor, Helsinki Local Division, 20 October 2023

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic application
Outcome (Dhenne Avocats summary)
GXD-Bio doit constituer une garantie de 112 000 euros pour les frais des défenderesses avant le 15 janvier 2025, la demande de décision par défaut anticipée est rejetée comme prématurée.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 346 403Mentioned in the analysis (role not qualified)
Also mentioned in 2 other decision(s): GXD-Bio v Myriad International (CFI, UPC_CFI_437/2024, 19 December 202 · GXD-Bio v Myriad Genetics (CFI, 14 February 2025)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.